

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma ID1589**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

It has been suggested that there is inequality of access to photo therapy, they key comparator in this scope.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Lack of access to phototherapy is not considered to be an equality issue. If chlormethine gel was recommended for treating mycosis fungoides-type cutaneous T-cell lymphoma, the access to chlormethine gel would be the same for all patients.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes have been made.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

**Approved by Associate Director (name):** ...Janet Robertson

**Date:**